Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $80.0 million.

  • Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) rose 1158.39% to $80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.0 million, marking a year-over-year increase of 1158.39%. This contributed to the annual value of $71.4 million for FY2024, which is 69.35% down from last year.
  • Latest data reveals that Kiniksa Pharmaceuticals International reported Shares Outstanding (Diluted Average) of $80.0 million as of Q3 2025, which was up 1158.39% from $77.9 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's 5-year Shares Outstanding (Diluted Average) high stood at $80.0 million for Q3 2025, and its period low was $68.3 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $71.4 million, with a median of $70.6 million in 2022.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) tumbled by 87.96% in 2024, and later surged by 1158.39% in 2025.
  • Kiniksa Pharmaceuticals International's Shares Outstanding (Diluted Average) (Quarter) stood at $68.6 million in 2021, then increased by 2.69% to $70.4 million in 2022, then grew by 2.13% to $71.9 million in 2023, then decreased by 0.69% to $71.4 million in 2024, then rose by 12.06% to $80.0 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $80.0 million in Q3 2025, compared to $77.9 million in Q2 2025 and $76.1 million in Q1 2025.